› Forums › General Melanoma Community › New in Community, Need your urgent Help
- This topic has 9 replies, 2 voices, and was last updated 9 years, 2 months ago by
FriendofMari.
- Post
-
- March 16, 2016 at 6:42 am
Hello everyone, Mari is the closest friend of mine, she was diagnosed choroidal malignang Melanoma in 2014 and had a surgery of enucleation in May 2014, since that everything seemed to be ok, buT unfortunately, in Januari 2016, were found 6 mets in liver, the biggest one is 1.5 sm. she is taking her treatment in Turkey, achebadim Clinic with Keytruda, she had injected the second one this week. She feels ok, but we have a very huge problem about money, Unfortunately our insurance does not cover fees, so we have to gather money every 3 weeks, for 7500 euro per injection. please help us about this problem, every $ matters.
Here is a link of fundrising. please share among your friends.
https://www.gofundme.com/allofusformariAlso, we have a question, is here anyone who is NED after keytruda treatment? and how long is it lasting? thank you for your respond, sincerely, Maris friend Nino 🙂
- Replies
-
-
- March 17, 2016 at 9:47 am
No answer ? okey….
-
- March 17, 2016 at 9:47 am
No answer ? okey….
-
- March 17, 2016 at 9:47 am
No answer ? okey….
-
- March 18, 2016 at 2:01 am
Dear Nino,
I am sorry that you and your friend are facing financial difficulties to attain treatment as well as melanoma. As far as financing….sometimes if you contact the company (merck…in the case of Keytruda) you can attain some financial help. As far as Keytruda results…. pembolizumab/keytruda and nivolumab/opdivo are anti-PD1 immunotherapy products. They both have about a 40% response rate. Many here have had positive responses to that therapy. Some of us have managed to rid ourselves of any signs of disease, others gained a partial response, others have stable disease. You can search this forum for further discussion. In the US…the FDA approved both of these anti-PD1 products only in 2011…treatment is administered approximately 2 years or longer. So….we do not have any quantifiable duration of response numbers. I am sure more data in that area will be presented at ASCO (the American Society of Clinical Oncology's annual meeting in June) this year…and many eagerly await that information. There are many studies addressing anti-PD1, keytruda, and melanoma generally on my blog…use the search bubble if you are interested. On a personal note….I am a melanoma patient….first diagnosed in 2003…Stage IV since 2010….NED since that point as well….having had nivo/Opdivo for 2 1/2 years. Hope that helps. Celeste
-
- March 18, 2016 at 2:01 am
Dear Nino,
I am sorry that you and your friend are facing financial difficulties to attain treatment as well as melanoma. As far as financing….sometimes if you contact the company (merck…in the case of Keytruda) you can attain some financial help. As far as Keytruda results…. pembolizumab/keytruda and nivolumab/opdivo are anti-PD1 immunotherapy products. They both have about a 40% response rate. Many here have had positive responses to that therapy. Some of us have managed to rid ourselves of any signs of disease, others gained a partial response, others have stable disease. You can search this forum for further discussion. In the US…the FDA approved both of these anti-PD1 products only in 2011…treatment is administered approximately 2 years or longer. So….we do not have any quantifiable duration of response numbers. I am sure more data in that area will be presented at ASCO (the American Society of Clinical Oncology's annual meeting in June) this year…and many eagerly await that information. There are many studies addressing anti-PD1, keytruda, and melanoma generally on my blog…use the search bubble if you are interested. On a personal note….I am a melanoma patient….first diagnosed in 2003…Stage IV since 2010….NED since that point as well….having had nivo/Opdivo for 2 1/2 years. Hope that helps. Celeste
-
- March 18, 2016 at 10:16 am
Thank you very much for your response, any information is very helpful and useful for us, I hope That everything will be ok with you and with my friend too, Ill read your blog, thank you again, we will try to contact to Merck, sincerely, Nino:)
-
- March 18, 2016 at 10:16 am
Thank you very much for your response, any information is very helpful and useful for us, I hope That everything will be ok with you and with my friend too, Ill read your blog, thank you again, we will try to contact to Merck, sincerely, Nino:)
-
- March 18, 2016 at 10:16 am
Thank you very much for your response, any information is very helpful and useful for us, I hope That everything will be ok with you and with my friend too, Ill read your blog, thank you again, we will try to contact to Merck, sincerely, Nino:)
-
- March 18, 2016 at 2:01 am
Dear Nino,
I am sorry that you and your friend are facing financial difficulties to attain treatment as well as melanoma. As far as financing….sometimes if you contact the company (merck…in the case of Keytruda) you can attain some financial help. As far as Keytruda results…. pembolizumab/keytruda and nivolumab/opdivo are anti-PD1 immunotherapy products. They both have about a 40% response rate. Many here have had positive responses to that therapy. Some of us have managed to rid ourselves of any signs of disease, others gained a partial response, others have stable disease. You can search this forum for further discussion. In the US…the FDA approved both of these anti-PD1 products only in 2011…treatment is administered approximately 2 years or longer. So….we do not have any quantifiable duration of response numbers. I am sure more data in that area will be presented at ASCO (the American Society of Clinical Oncology's annual meeting in June) this year…and many eagerly await that information. There are many studies addressing anti-PD1, keytruda, and melanoma generally on my blog…use the search bubble if you are interested. On a personal note….I am a melanoma patient….first diagnosed in 2003…Stage IV since 2010….NED since that point as well….having had nivo/Opdivo for 2 1/2 years. Hope that helps. Celeste
-
- You must be logged in to reply to this topic.